Imma Grau1, Carmen Ardanuy2, Meritxell Cubero3, Miguel A Benitez4, Josefina Liñares5, Roman Pallares6. 1. Infectious Diseases Department, Hospital Bellvitge, Ciberes, Idibell, University of Barcelona, Barcelona, Spain. Electronic address: igrau@idibell.cat. 2. Microbiology Department, Hospital Bellvitge, Ciberes, Idibell, University of Barcelona, Barcelona, Spain. Electronic address: c.ardanuy@bellvitgehospital.cat. 3. Microbiology Department, Hospital Bellvitge, Ciberes, Idibell, University of Barcelona, Barcelona, Spain. Electronic address: meritxellcubero@gmail.com. 4. Microbiology Department, Hospital Moises Broggi, Sant Joan Despi, Barcelona, Spain. Electronic address: mabenitez@cli.scs.es. 5. Microbiology Department, Hospital Bellvitge, Ciberes, Idibell, University of Barcelona, Barcelona, Spain. Electronic address: fina.linares@bellvitgehospital.cat. 6. Infectious Diseases Department, Hospital Bellvitge, Ciberes, Idibell, University of Barcelona, Barcelona, Spain. Electronic address: rpallares@ub.edu.
Abstract
OBJECTIVE: To determine changes in mortality among adults with invasive pneumococcal disease (IPD) after introducing pneumococcal conjugate vaccines (PCVs) in children. METHODS: An active surveillance of adults with culture-proven IPD in Barcelona. Serotype-specific mortality and rates of disease and death were analysed in three periods: baseline (1994-2001), PCV7 (2002-2009) and PCV13 (2010-2013). RESULTS: Overall, IPD caused by PCV7 serotypes was associated with increased case fatality rate (24 percent). In patients 18-64 years (baseline vs. PCV7 vs. PCV13 periods), case fatality rate from IPD decreased (22 vs.14 vs. 12 percent), and it was associated with a decline in PCV7 serotypes (3.56 vs. 2.80 vs. 1.49 cases/10(5) person-years) and in PCV7 serotypes-specific death (0.74 vs. 0.53 vs. 0.09 deaths/10(5) person-years). In patients ≥65 years, case fatality rate did not change (24 vs. 22 vs. 24 percent); however, there was a decline in PCV7 serotypes-specific death (4.94 vs. 3.58 vs. 2.45 deaths/10(5) person-years), and an increase in non-PCV serotypes-specific death (2.55 vs. 3.70 vs. 4.09 deaths/10(5) person-years). CONCLUSIONS: The use of PCVs for children was associated with a reduction of mortality from IPD in adults 18-64 years, through the indirect effect of herd protection. In older adults, age-related factors could play a role in IPD mortality.
OBJECTIVE: To determine changes in mortality among adults with invasive pneumococcal disease (IPD) after introducing pneumococcal conjugate vaccines (PCVs) in children. METHODS: An active surveillance of adults with culture-proven IPD in Barcelona. Serotype-specific mortality and rates of disease and death were analysed in three periods: baseline (1994-2001), PCV7 (2002-2009) and PCV13 (2010-2013). RESULTS: Overall, IPD caused by PCV7 serotypes was associated with increased case fatality rate (24 percent). In patients 18-64 years (baseline vs. PCV7 vs. PCV13 periods), case fatality rate from IPD decreased (22 vs.14 vs. 12 percent), and it was associated with a decline in PCV7 serotypes (3.56 vs. 2.80 vs. 1.49 cases/10(5) person-years) and in PCV7 serotypes-specific death (0.74 vs. 0.53 vs. 0.09 deaths/10(5) person-years). In patients ≥65 years, case fatality rate did not change (24 vs. 22 vs. 24 percent); however, there was a decline in PCV7 serotypes-specific death (4.94 vs. 3.58 vs. 2.45 deaths/10(5) person-years), and an increase in non-PCV serotypes-specific death (2.55 vs. 3.70 vs. 4.09 deaths/10(5) person-years). CONCLUSIONS: The use of PCVs for children was associated with a reduction of mortality from IPD in adults 18-64 years, through the indirect effect of herd protection. In older adults, age-related factors could play a role in IPD mortality.
Authors: C Hays; Q Vermee; A Agathine; A Dupuis; E Varon; C Poyart; M-C Ploy; J Raymond Journal: Eur J Clin Microbiol Infect Dis Date: 2016-12-20 Impact factor: 3.267
Authors: David A Nace; Laurie R Archbald-Pannone; Muhammad S Ashraf; Paul J Drinka; Elizabeth Frentzel; Swati Gaur; Dheeraj Mahajan; David R Mehr; William C Mercer; Philip D Sloane; Robin L P Jump Journal: J Am Med Dir Assoc Date: 2017-02-01 Impact factor: 4.669
Authors: Carlos M Luna; Laura Pulido; Michael S Niederman; Alberto Casey; Diego Burgos; Sebastián D Leiva Agüero; Alejandra Grosso; Evangelina Membriani; Andrea C Entrocassi; Marcelo Rodríquez Fermepin; Carlos A Vay; Susana Garcia; Angela Famiglietti Journal: Pneumonia (Nathan) Date: 2018-09-25
Authors: Aida González-Díaz; Miguel P Machado; Jordi Càmara; José Yuste; Emmanuelle Varon; Miriam Domenech; María Del Grosso; José María Marimón; Emilia Cercenado; Nieves Larrosa; María Dolores Quesada; Dionisia Fontanals; Assiya El-Mniai; Meritxell Cubero; João A Carriço; Sara Martí; Mario Ramirez; Carmen Ardanuy Journal: Euro Surveill Date: 2020-04